Alexander M Sele

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2019
Publications (10 Years): 3

Top Topics

Temporal Lobe Epilepsy

Cell Proliferation

Top Venues

Journal of medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Denise Rageot, Thomas Bohnacker, Erhan Keles, Jacob A McPhail, Reece M Hoffmann, Anna Melone, Chiara Borsari, Rohitha Sriramaratnam, Alexander M Sele, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, John E Burke, Matthias P Wymann
(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. Journal of medicinal chemistry 62 (13) (2019)
Chiara Borsari, Denise Rageot, Alix Dall'Asen, Thomas Bohnacker, Anna Melone, Alexander M Sele, Eileen Jackson, Jean-Baptiste Langlois, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, Matthias P Wymann
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. Journal of medicinal chemistry 62 (18) (2019)
Denise Rageot, Thomas Bohnacker, Anna Melone, Jean-Baptiste Langlois, Chiara Borsari, Petra Hillmann, Alexander M Sele, Florent Beaufils, Marketa Zvelebil, Paul Hebeisen, Wolfgang Löscher, John E Burke, Doriano Fabbro, Matthias P Wymann
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. Journal of medicinal chemistry 61 (22) (2018)